Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $23.4100 (1.34%) ($21.4200 - $23.6300) on Mon. Aug. 13, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.57% (three month average) | RSI | 32 | Latest Price | $23.4100(1.34%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.8% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) IBB(19%) ONLN(19%) XOP(18%) IWM(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.285% in a week (0% probabilities). UNG(-10%) VIXM(-9%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.285% (StdDev 2.57%) | Hourly BBV | 0 () | Intraday Trend | 2.8% | | | |
|
1 - 5 Day Possible Target | $12.73(-45.62%) | Resistance Level | $25.37 | 5 Day Moving Average | $23.9(-2.05%) | 10 Day Moving Average | $24.23(-3.38%) | 20 Day Moving Average | $25.37(-7.73%) | To recent high | -28.3% | To recent low | 1.3% | Market Cap | $662m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |